Money & Markets
Money & Markets
Big money is flowing into AI infrastructure and drug discovery, while the market's appetite for pure tech plays is shifting. Here's what moving this week.
MyAIGuide Weekly · Issue 3 · Sep 21–27, 2026
- 1Basecamp Research Raises $140M Series C to Train New EDEN Models
Basecamp Research's $140M raises stakes in AI-designed drugs—watch this space if your company bets on biotech innovation or supply chain pharma.
AI Funding & Investments
- 2Finnish AI cloud startup Verda raises $189 million Series B, crossing $1 billion valuation
Verda's $1B+ valuation shows AI cloud infrastructure is now a serious investment category; consider whether your current cloud vendor is keeping pace.
AI Funding & Investments
- 3Neocloud Nscale Raises $3.36B in New Funding
Neocloud Nscale's $3.36B haul signals institutional money is consolidating around fewer, larger AI plays—your vendor choices may narrow.
AI Funding & Investments
- 4AI Drug Discovery Firm Iambic Therapeutics Plans Nasdaq Debut With Nvidia Backing
Iambic's Nasdaq filing and Nvidia backing confirm AI drug discovery is crossing into mainstream finance; healthcare teams should track this sector.
AI Mergers & Acquisitions
- 5One key part of the AI trade has decoupled from the rest. Why that is, and whether it can come back
Industrial stocks outpacing AI stocks suggests the trade may be maturing; investors are rotating from hype into actual deployed applications.
AI in Finance
